Le Cesne A, Bauer S, Demetri GD, et al. - Researchers planned a retrospective subgroup analyses of a phase 3 trial to determine how the safety and effectiveness of pazopanib in advanced soft tissue sarcomas (aSTS) may be impacted by patient features, prior lines of therapy, dose intensity, and dose modifications. In the PALETTE study, pazopanib was compared with placebo in patients with aSTS (age ≥ 18 years) who experienced disease progression during or after previous chemotherapy, as well as the single-agent activity of pazopanib in aSTS. Patients aged < 65 and ≥ 65 years had similar median progression-free survival (mPFS). Both the age groups had similar rates of dose reductions, dose interruptions, and serious AEs, but older patients had higher adverse events (AEs) resulting in study discontinuation. Patients taking pazopanib after only one line of therapy had longer mPFS. In addition, irrespective of patient age or dose alterations used to manage toxicity, mPFS with pazopanib was maintained.